I want to tell you about one of the best strategies in the world for beating an overvalued market. I use it to generate thousands of dollars in "Instant Income" from the best companies in the world.
If you haven't guessed it already, my strategy involves selling options. And right now, we have a huge opportunity...
In just a minute, I’ll give you five potential trades to consider today for collecting immediate income. First, let me explain how it works with a couple of past examples.
Recently, subscribers to my Income Trader newsletter made $130 in "Instant Income" from a $520 "down payment" on Questcor Pharmaceuticals (Nasdaq: QCOR). That's an immediate return of 25% in 43 days, or 212% a year. And back in July, I collected $100 in "Instant Income" from OSI Systems (Nasdaq: OSIS) for every $900 I set aside. That’s an 11.1% return in 45 days, or 90.1% a year. Remember, this is how much income we made per contract. You can scale up as much as you want.
Top 10 Clean Energy Stocks To Own Right Now: Intex Resources ASA (ITX)
Intex Resources ASA is a Norway-based mining and exploration company that focuses primarily on mineral and metal deposits. As of 31 December 2011, the Company�� project portfolio consisted of Mindoro Nickel in the Philippines, the Nordli molybdenum project in Norway, the Maniitsoqdiamond project in West Greenland, as well as several grassroots exploration projects. The Company focuses primarily on the Mindoro Nickel nickel-laterite deposit. As of December 31, 2011, the Company had a total of four wholly owned subsidiaries, namely Molynor AS, IceFire Diamonds AS, Intex Resources AS and Norex Resources AS. As of December 31, 2011, its largest shareholder was Lybica Holding B.V., which held 21.71% shares. Advisors' Opinion:- [By Sarah Jones]
Inditex SA (ITX) added 3.5 percent to 101.30 euros after reporting a 5.2 percent increase in first-quarter sales to 3.59 billion euros. The world�� biggest clothing retailer also forecast stable profitability even after first-quarter profit advanced at the slowest pace in four years.
5 Best Heal Care Stocks To Own For 2014: LSI Logic Corporation (LSI)
LSI Corporation designs, develops, and markets storage and networking semiconductors worldwide. It offers integrated circuits for hard disk and tape drive solutions, which are used to store and retrieve data in personal computers, corporate network servers, archive/back-up devices, and consumer electronics products. The company�s storage electronics products include systems-on-a-chip, read channels, pre-amplifiers, serial physical interfaces, and hard disk controllers, as well as custom firmware required to read, write, and protect data. It also offers pre-amplifiers, which are used to amplify the initial signal to and from the drive disk heads; and solutions that transmit data between a host computer and storage peripheral devices. In addition, the company provides custom and standard networking solutions that include chips, such as network processors, digital signal processors, content-inspection processors, traffic shaping devices, and physical layer devices, as well a s software, evaluation systems, and reference designs for office, home office, and small-to-medium business applications; flash storage processors; server storage semiconductor products, and server RAID adapters and software; and high-speed interface intellectual property that combine with customers� intellectual property to provide a connection to the SAN, memory systems, and host buses. Further, it offers networking solutions include communication processors, network processors, media processors, content-inspection processors, and physical layer devices, as well as software tools and segment specific applications, evaluation systems, and reference designs. The company was formerly known as LSI Logic Corporation and changed its name to LSI Corporation in April 2007. The company was founded in 1980 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By ICRAOnline]
Revenue for the last quarter stood at $73.4 million, up 27.9% from the year-ago quarter. This was primarily driven by the growth in memory technology licensing, coupled with impressive performance of its security technology licensing business. During the quarter, Rambus also signed new licensing agreements with tech giant Samsung Electronics, Micron Technology (MU), STMicroelectronics (STM), LSI Semiconductor (LSI) and SK Hynix. However, the company�� LED lighting business failed to make any significant contribution.
- [By Rich Smith]
It might not be obvious to the casual observer, but right now, today, LSI (NASDAQ: LSI ) stock offers one of the best values available in the semiconductor industry. Why?
- [By Patricio Kehoe]
Finally, I always like to see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the return on equity. With a ROE of -7.19% is below the industry mean of 5.06%. Other more attractive option in terms of this ratio is LSI Corporation (LSI) with a ROE of 8.68%.
5 Best Heal Care Stocks To Own For 2014: Pernix Therapeutics Holdings Inc (PTX)
Pernix Therapeutics Holdings, Inc. (Pernix), incorporated in November 8, 1996, is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas. It manages a portfolio of branded and generic products and theobromine, a non-codeine, cough suppressant product candidate in development. The Company�� branded products for the pediatrics market include CEDAX, an antibiotic for middle ear infections, NATROBA, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (BROVEX, ALDEX and PEDIATEX). It also markets REZYST IM, which is a probiotic blend to promote dietary management. Pernix markets generic products through its wholly owned subsidiary, Macoven Pharmaceuticals, LLC. In January 2013, the Company acquired Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. In March 2013, the Company acquired Somaxon Pharmaceuticals Inc. In September 2013, Pernix Therapeutics Holdings, Inc. completed the sale of certain non-core assets to Breckenridge Pharmaceutical, Inc.
The Company�� customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sells products directly to drug wholesalers, which in turn distribute the products to retail drug stores, mass merchandisers and grocery store pharmacies.
ALDEX Line
ALDEX is a line of antihistamines, decongestants and cough suppressants that are indicated for the temporary relief of respiratory allergies, allergic rhinitis and symptoms of the common cold. The Company�� ALDEX product line is marketed in a range of formulations and combinations using different drug-delivery methodologies to target specific segments of the antihistamine, decongestant and cough suppressant markets. Two used decongestants ar! e phenylephrine and pseudoephedrine.
BROVEX Line
The BROVEX line is a line of antihistamine combinations with the active pharmaceutical ingredient (API) brompheniramine maleate, part of the first generation class of antihistamines called alkylamines that are indicated for the temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose due to hay fever or other respiratory allergies. Its BROVEX product line is marketed in a range of formulations and combinations to target specific segments of the antihistamine market. The Company completed the conversion of the BROVEX product family to over-the-counter (OTC) monograph from DESI drugs, in April 2011.
CEDAX Line
CEDAX is a third generation oral cephalosporin indicated for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza or streptococcus pyogenes. The Company sells a range of dosages utilizing both capsule and oral suspension drug delivery methodologies. It also owns a trademark on the name CEDAX in the United States.
NATROBA Line
NATROBA Topical Suspension is a prescription medicine used to treat head lice (pediculosis capitis) in adults and children four years of age and older. NATROBA contains the active ingredient spinosad, which is derived from a naturally occurring soil bacterium.
PEDIATEX Line
As of December 31, 2011, the only product that the Company marketed and sold in its PEDIATEX line is PEDIATEX TD. PEDIATEX TD is an antihistamine/nasal decongestant combination liquid for oral administration. Each 1 milliliter dose contains the API Tripolidine HC1 and Pseudoephedrine HC1. Tripolidine HC1 is a first generation antihistamine in the alkylamine class. Pseudoephedrine, a decongestant, is a sympathomimetic, which acts on alpha-adrenergic receptors in the mucosa of the respiratory tract, producing vasoconstriction and having minimal eff! ect on be! ta-receptors. It therefore functions as an oral nasal decongestant with minimal central nervous system stimulation.
REZYST Line
REZYST IM is a probiotic blend that promotes the dietary management of patients with the distinctive nutritional requirements associated with the gastro-intestinal flora. It is formulated to improve the digestive health of patients by replacing the active cultures altered by diet, stress, and antibiotics.
Product Candidates in Development
Product candidates in development include Theobromine. Theobromine is an alkaloid naturally present in dark chocolate which is an existing human metabolite of caffeine. The Company is working on several other product candidates, which includes a prescription product for the pediatrics market. In March 2012, the Company entered into a product development agreement with a private company for this product.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare stocks gained Wednesday, with Senomyx (NASDAQ: SNMX) leading advancers after the company announced a research agreement with PepsiCo (NYSE: PEP). Among the leading sector stocks, gains came from Pernix Therapeutics Holdings (NASDAQ: PTX), Albany Molecular Research (NASDAQ: AMRI) and Gentiva Health Services (NASDAQ: GTIV). - [By Michael Douglass and David Williamson]
Shares of�Pernix Therapeutics� (NASDAQ: PTX ) soared 31% yesterday after the company revealed that it had bought the U.S. rights to�GlaxoSmithKline's (NYSE: GSK ) Treximet (which helps treat migraines in adults) for $250 million upfront (and some potential additional payments later). The importance of this purchase cannot easily be overstate for Pernix -- the company had $85 million in revenue last year, while Treximet on its own brought in $79 million -- and Pernix clearly sees some additional upside potential for the drug, whether it's through a potential indication expansion (to pediatric patients) or through synergies with Pernix's current salesforce.
5 Best Heal Care Stocks To Own For 2014: Abby Inc (ABBY)
Abby, Inc., incorporated on December 11, 2000, is an exploration-stage company. The Company is in the business of natural gas exploration. On September 17, 2010, the Company acquired the Westrose property gas concession option from Mitchel Vestco Inc. As of November 30, 2010, the Company had completed Phase One of its exploration program. As of November 30, 2010, it had not generated any revenues.
The Westrose Property
The Westrose property is located in Alberta, Canada. The property consists of 640 acres. As of August 22, 2011, the Company had not commenced any exploration or work on the concession.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:
No comments:
Post a Comment